Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Current Deferred Revenue (2016 - 2026)

Iradimed has reported Current Deferred Revenue over the past 14 years, most recently at $7.2 million for Q1 2026.

  • Quarterly Current Deferred Revenue rose 23.34% to $7.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.2 million through Mar 2026, up 23.34% year-over-year, with the annual reading at $2.9 million for FY2025, 45.35% down from the prior year.
  • Current Deferred Revenue was $7.2 million for Q1 2026 at Iradimed, up from $2.9 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $7.2 million in Q1 2026 and troughed at $1.6 million in Q3 2022.
  • The 5-year median for Current Deferred Revenue is $2.6 million (2023), against an average of $3.1 million.
  • The largest YoY upside for Current Deferred Revenue was 148.03% in 2025 against a maximum downside of 45.35% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $3.4 million in 2022, then decreased by 23.8% to $2.6 million in 2023, then skyrocketed by 104.36% to $5.3 million in 2024, then tumbled by 45.35% to $2.9 million in 2025, then skyrocketed by 149.18% to $7.2 million in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Current Deferred Revenue are $7.2 million (Q1 2026), $2.9 million (Q4 2025), and $3.2 million (Q3 2025).